Next Article in Journal
Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease
Previous Article in Journal
Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients
Open AccessArticle

Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion

1
Department of Drug Information and Communication, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan
2
Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan
3
Department of Gastroenterology, Chiba Central Medical Center, 1835-1 Kasoricho, Wakaba-ku, Chiba, 264-0017, Japan
4
Department of Clinical Education and Research, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan
*
Author to whom correspondence should be addressed.
Pharmaceutics 2010, 2(3), 300-312; https://doi.org/10.3390/pharmaceutics2030300
Received: 24 June 2010 / Accepted: 1 September 2010 / Published: 9 September 2010
This study investigated gene expression of drug resistance factors in biopsy tissue samples from hepatocellular carcinoma (HCC) patients undergoing chemotherapy by platinum complex. Liver biopsy was performed to collect tissue from the tumor site (T) and the non-tumor site (NT) prior to the start of treatment. For drug-resistant factors, drug excretion transporters cMOAT and MDR-1, intracellular metal binding protein MT2, DNA repair enzyme ERCC-l and inter-nucleic cell transport protein MVP, were investigated. The comparison of the expression between T and NT indicated a significant decrease of MT2 and MDR-1 in T while a significant increase in ERCC-1 was noted in T. Further, expression was compared between the response cases and non-response cases using the ratios of expression in T to those in NT. The response rate was significantly low in the high expression group when the cutoff value of cMOAT and MT2 was set at 1.5 and 1.0, respectively. Furthermore, when the patients were classified into A group (cMOAT ≧ 1.5 or MT2 ≧ 1.0) and B group (cMOAT < 1.5 and MT2 < 1.0), the response rate of A group was significantly lower than B group when we combined the cutoff values of cMOAT and MT2. It is considered possible to estimate the therapeutic effect of platinum complex at a high probability by combining the expression condition of these two genes. View Full-Text
Keywords: canalicular multispecific organ anion transporter; chemotherapy; drug-resistance; hepatocellular carcinoma; metallothionein; platinum complex canalicular multispecific organ anion transporter; chemotherapy; drug-resistance; hepatocellular carcinoma; metallothionein; platinum complex
Show Figures

Figure 1

MDPI and ACS Style

Sakurada, T.; Yoshikawa, M.; Sunaga, M.; Kobayashi, E.; Satoh, N.; Yokosuka, O.; Ueda, S. Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion. Pharmaceutics 2010, 2, 300-312.

AMA Style

Sakurada T, Yoshikawa M, Sunaga M, Kobayashi E, Satoh N, Yokosuka O, Ueda S. Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion. Pharmaceutics. 2010; 2(3):300-312.

Chicago/Turabian Style

Sakurada, Tomoya; Yoshikawa, Masaharu; Sunaga, Masahiko; Kobayashi, Eriko; Satoh, Nobunori; Yokosuka, Osamu; Ueda, Shiro. 2010. "Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion" Pharmaceutics 2, no. 3: 300-312.

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop